New chief commercial officer to help UroGen keep growing

4 June 2024
biotech-appt

Bladder cancer specialist UroGen Pharma (Nasdaq: URGN) has appointed David Lin as chief commercial officer.

The New Jersey, USA-based firm has made the appointment in the run-up to a potential launch for lead candidate UGN-102 (mitomycin).

Mr Lin joins UroGen with experience from his tenure at Bristol Myers Squibb (NYSE: BMY), where he successfully launched two CAR T therapies as head of US cell therapy.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical